Glaucoma treatment pharma company Aerie closes $41M venture round
Glaucoma treatment company Aerie Pharmaceuticals has closed a $41.3 million round of financing as the company prepares for phase III trials. Aerie’s glaucoma treatment candidate is AR-12286. The compound is what’s called a Rho-kinase inhibitor. Aerie has said AR-12286’s mechanism of action repairs the diseased tissue, restoring normal function to the eye. No glaucoma medicines currently available are Rho-kinase inhibitors. During the recent CED Biotech/Life Science conference in Raleigh, North Carolina, Aerie said that it has successfully completed phase II studies and is ready to move into phase III.